Neuren Pharmaceuticals announced the appointment of Jon Pilcher as Chief Executive Officer. The change follow Richard Treagus' decision to stand down after more than 7 years as Executive Chairman to enable him to focus on his other business interests. Jon has consistently played a key role alongside Richard in the business and has strong established relationships with business partners and investors. Together with the additional appointments made to strengthen the board two years ago, this means the Company is very well placed to make a smooth transition. Richard will be available to assist the board and management as the changes are implemented. Jon has played a central role in all aspects of Neuren's operations and strategy since 2013 as CFO and is ideally suited to lead Neuren as it moves forward to realise the value of two drugs across multiple childhood disorders with urgent unmet need. Combining financial and capital markets expertise with a science background, Jon has extensive corporate and R&D executive experience in international listed pharmaceutical companies.